{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:14:27Z","timestamp":1792599267440,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ahj.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T09:30:37Z","timestamp":1714815037000},"page":"32-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Obicetrapib on top of maximally tolerated lipid\u2010modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN"],"prefix":"10.1016","volume":"274","author":[{"given":"Stephen J.","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ditmarsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam R.","family":"Brunham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Wuerdeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Neild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Kling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary R.","family":"Dicklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Ference","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.05.002_bib0001","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global Burden of Cardiovascular D, Risks C. Global Burden of Cardiovascular Diseases and Risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0002","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.05.002_bib0003","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0004","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Boren","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.05.002_bib0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.05.002_bib0006","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0007","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.05.002_bib0008","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0009","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.05.002_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia\u2013full report","volume":"8","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.008552","article-title":"Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events: systematic review and meta-analysis","volume":"15","author":"Wang","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2024.05.002_bib0012","doi-asserted-by":"crossref","first-page":"972-980 e1","DOI":"10.1016\/j.jacl.2018.04.002","article-title":"Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: a model that explores the efficacy of conventional and novel lipid-lowering therapy","volume":"12","author":"Hartgers","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0013","article-title":"Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease","volume":"2020","author":"Patel","year":"2020","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.ahj.2024.05.002_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0015","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0016","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.3390\/jcm12237432","article-title":"Evolution of more aggressive LDL-cholesterol targets and therapies for cardiovascular disease prevention","volume":"12","author":"Jones","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ahj.2024.05.002_bib0017","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/CIRCOUTCOMES.122.009787","article-title":"Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322,153 patients","volume":"16","author":"Navar","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2024.05.002_bib0018","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9149(97)00298-1","article-title":"The rule of 5 and the rule of 7 in lipid-lowering by statin drugs","volume":"80","author":"Roberts","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0019","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0020","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1210\/clinem\/dgad153","article-title":"Approach to the patient with a suboptimal statin response: causes and algorithm for clinical management","volume":"108","author":"Sun","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2024.05.002_bib0021","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Bytyci","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.05.002_bib0022","first-page":"1270","article-title":"Ezetimibe use and LDL-C goal achievement: a retrospective database analysis of patients with clinical atherosclerotic cardiovascular disease or probable heterozygous familial hypercholesterolemia","volume":"23","author":"Menzin","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ahj.2024.05.002_bib0023","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"DM","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0024","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0025","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J Intern Med"},{"key":"10.1016\/j.ahj.2024.05.002_bib0026","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","article-title":"Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy","volume":"2","author":"Navar","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0027","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jacl.2023.03.006","article-title":"Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice","volume":"17","author":"Bradley","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0028","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2021.08.035","article-title":"Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study","volume":"334","author":"Vrablik","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2024.05.002_bib0029","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ahj.2024.05.002_bib0030","article-title":"Optimal implementation of the 2019 ESC\/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study","volume":"31","author":"Brandts","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ahj.2024.05.002_bib0031","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bcp.12380","article-title":"Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects","volume":"78","author":"Ford","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0032","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.05.002_bib0033","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ahj.2024.05.002_bib0034","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial","volume":"17","author":"Ballantyne","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0035","doi-asserted-by":"crossref","DOI":"10.5551\/jat.64828","article-title":"Obicetrapib as an adjunct to stable statin therapy in Japanese subjects: results from a randomized phase 2 trial","author":"Harada-Shiba","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ahj.2024.05.002_bib0036","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cpt.700","article-title":"Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination","volume":"102","author":"Krishna","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2024.05.002_bib0037","unstructured":"Merck. Merck provides update on anacetrapib development program. In; 2017."},{"key":"10.1016\/j.ahj.2024.05.002_bib0038","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1172\/JCI118196","article-title":"Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency","volume":"96","author":"Ikewaki","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2024.05.002_bib0039","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/01.ATV.0000205595.19612.c9","article-title":"Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis","volume":"26","author":"Klerkx","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0040","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1172\/JCI80025","article-title":"Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects","volume":"125","author":"Millar","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2024.05.002_bib0041","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/MOL.0000000000000473","article-title":"Transintestinal cholesterol excretion in humans","volume":"29","author":"Reeskamp","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0042","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1161\/ATVBAHA.119.312952","article-title":"Simultaneous determination of biliary and intestinal cholesterol secretion reveals that CETP (cholesteryl ester transfer protein) alters elimination route in mice","volume":"39","author":"Li","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0043","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","article-title":"Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?","volume":"118","author":"Nurmohamed","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2024.05.002_bib0044","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (Cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/ph16070919","article-title":"Current management and future perspectives in the treatment of Lp(a) with a focus on the prevention of cardiovascular diseases","volume":"16","author":"Farina","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ahj.2024.05.002_bib0046","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1172\/JCI117537","article-title":"Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol","volume":"94","author":"Inazu","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2024.05.002_bib0047","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.05.002_bib0048","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrcardio.2017.156","article-title":"Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease","volume":"14","author":"Holmes","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0049","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169417","article-title":"Cholesteryl ester transfer protein inhibition reduces major adverse cardiovascular events by lowering apolipoprotein B levels","volume":"23","author":"Nelson","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ahj.2024.05.002_bib0050","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.05.002_bib0051","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/eurheartj\/ehab863","article-title":"Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease","volume":"43","author":"Group","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.05.002_bib0052","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.05.002_bib0053","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0054","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jacc.2022.01.010","article-title":"Key questions about familial hypercholesterolemia: JACC review topic of the week","volume":"79","author":"Sniderman","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0055","doi-asserted-by":"crossref","DOI":"10.1177\/10742484231186855","article-title":"Treatment with Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?","volume":"28","author":"Giglio","year":"2023","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ahj.2024.05.002_bib0056","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","article-title":"Obicetrapib: reversing the tide of CETP inhibitor disappointments","volume":"26","author":"Kastelein","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ahj.2024.05.002_bib0057","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.diabet.2018.02.005","article-title":"Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk","volume":"44","author":"Masson","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ahj.2024.05.002_bib0058","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.05.002_bib0059","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134725","article-title":"Statin treatment-induced development of type 2 diabetes: from clinical evidence to mechanistic insights","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ahj.2024.05.002_bib0060","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"Ruscica","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2024.05.002_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106972","article-title":"The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease","volume":"197","author":"Mehta","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ahj.2024.05.002_bib0062","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12933-022-01684-5","article-title":"Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)","volume":"21","author":"Banach","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ahj.2024.05.002_bib0063","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324001169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324001169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T09:26:54Z","timestamp":1740821214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324001169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":63,"alternative-id":["S0002870324001169"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.05.002","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obicetrapib on top of maximally tolerated lipid\u2010modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}